

Written Comments Guide

FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds

August 25, 2026, 10:00 a.m. – 4:00 p.m. ET

On **August 25, 2026**, the U.S. Food and Drug Administration (FDA) is hosting a hybrid meeting, **Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds**. The PFDD will be used by the FDA to obtain input from patients, patient representatives, and care partners about their experiences with nonhealing wounds, including daily impact, management and treatment, and consider when determining whether to participate in a clinical trial. The meeting is public and includes an opportunity for voluntary community participation through written comments and attendance.

We encourage you to participate in this process by **submitting a public comment and attending the meeting either in-person or virtually** via the webcast. Attendees will have dedicated opportunities to share experiences and insights during the multiple open discussion portions of the agenda. **[Register to attend here.](#)**

Comment Submissions

*Docket ID FDA-2026-N-5057 for Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request for Comments, Meeting Date: August 25, 2026, **Comment Deadline: October 26, 2026***

Written comments from the public are due by **October 26, 2026**. Please **submit a clear and condensed comment** that includes your story, experiences, and the impact of nonhealing chronic wounds in the comment box. You can also upload any relevant documents to attach to your submission. These documents can include past testimony, published research, and relevant policies.

Written comments **must be submitted online [here](#)**. All comments must include whether you are writing on behalf of yourself or an organization. Be sure to fill out the relevant information under whichever category you choose.

Comments received **on or before October 26th** will go to the FDA and will be taken into consideration. Please keep in mind that **all submissions are public**, and **please do not include any confidential or sensitive information about yourself or anyone else**.

Suggested Topics

Consider when you're writing your public comment: *How do chronic, nonhealing wounds impact the lives of people living with SCD?* We suggest focusing on the following information:

- *How do nonhealing chronic wounds affect daily life?* This can include health, emotional wellbeing, mobility, work, relationships, and quality of life.
- *What has your experience been with current treatments and care?* What has helped, what has not worked, and what challenges or burdens have you experienced?
- *Beyond just closing the wound, what does healing look like for you?*
- *What would make someone more or less likely to participate in a clinical trial?*
- *What is something you want the FDA to know about nonhealing chronic wounds in the SCD community?*

Chronic, nonhealing wounds, such as leg ulcers, are a debilitating excruciating symptom of sickle cell disease. Your engagement can help inform key decision-makers. We encourage you to participate in the meeting by attending in-person or by participating virtually via the webcast. Attendees will have dedicated opportunities to share experiences and insights during the multiple open discussion portions of the agenda. Please do not hesitate to contact Alyssa Davenport (adavenport@sickcells.org) with questions.